middle.news
CSL Unveils $500m Cost-Cutting Plan and CSL Seqirus Demerger in FY25 Results
7:49am on Tuesday 19th of August, 2025 AEST
•
Healthcare
Read Story
CSL Unveils $500m Cost-Cutting Plan and CSL Seqirus Demerger in FY25 Results
7:49am on Tuesday 19th of August, 2025 AEST
Key Points
5% revenue growth and 14% NPATA increase at constant currency
Strategic transformation targeting $500 million annual pre-tax savings by FY28
Intent to demerge CSL Seqirus into a standalone ASX-listed vaccine company by FY26
Multi-year share buyback program reintroduced starting FY26
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CSL (ASX:CSL)
OPEN ARTICLE